Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novelix PharmaceuticalsBOM:536565 +5.00%62 Current Ratio is 2.14 as of Mar. 2026, which is 81% below its 10-year median of 11.02. GuruFocus rates BOM:536565 with a GF Score™ of 62/100 and a GF Value™ of ₹145.37 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 119 Medical Distribution companies, Novelix Pharmaceuticals ranks better than 79.83% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Novelix Pharmaceuticals's current ratio for the quarter that ended in Mar. 2026 was 2.14.
Novelix Pharmaceuticals has a current ratio of 2.14. It generally indicates good short-term financial strength.
The historical rank and industry rank for Novelix Pharmaceuticals's Current Ratio or its related term are showing as below:
BOM:536565'
s Current Ratio Range Over the Past 10 Years
Min: 2.14 Med: 11.02 Max: 564.89
Current: 2.14
During the past 13 years, Novelix Pharmaceuticals's highest Current Ratio was 564.89. The lowest was 2.14. And the median was 11.02.
BOM:536565's Current Ratio is ranked better than 79.83% of 119
companies
in the Medical Distribution industry
Industry Median: 1.4
vs BOM:536565: 2.14
Novelix Pharmaceuticals (BOM:536565) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Novelix Pharmaceuticals Current Ratio Related Terms
Novelix Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:536565 vs MCK, CAH, COR: Current Ratio Comparison
For the Medical Distribution subindustry, Novelix Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novelix Pharmaceuticals Current Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Novelix Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Novelix Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelix Pharmaceuticals (BOM:536565) has a Current Ratio of 2.14 as of Mar. 2026. This is 81% below median its historical median of 11.02. Over the past decade, Novelix Pharmaceuticals' Current Ratio has ranged from 2.14 to 564.89. According to the industry distribution chart, Novelix Pharmaceuticals ranks #24 out of 119 companies in the Medical Distribution industry, placing it in the top 20.2%.
Is Novelix Pharmaceuticals' Current Ratio too high?
Novelix Pharmaceuticals' current Current Ratio of 2.14 is 81% below median its 10-year median of 11.02. Over the past 10 years, this metric has ranged from a low of 2.14 to a high of 564.89. The Medical Distribution industry median Current Ratio is 1.40. Novelix Pharmaceuticals' value of 2.14 is 52.9% above this industry median. Based on the distribution chart, Novelix Pharmaceuticals ranks #24 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Novelix Pharmaceuticals has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' Current Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Novelix Pharmaceuticals ranks #24 out of 119 companies for Current Ratio. This places Novelix Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.40. Novelix Pharmaceuticals' value of 2.14 is 52.9% above this benchmark. Historically, Novelix Pharmaceuticals' own Current Ratio has ranged from 2.14 to 564.89 over the past decade. While the company's 10-year median is 11.02 vs. the industry median of 1.40, Novelix Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Distribution company?
The median Current Ratio among Medical Distribution companies is 1.40, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novelix Pharmaceuticals's current Current Ratio of 2.14 is 52.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Current Ratio is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novelix Pharmaceuticals's current Current Ratio is 2.14, which is 81% below median its own 10-year median of 11.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Novelix Pharmaceuticals (BOM:536565) is currently considered Possible Value Trap. The stock's GF Value™ is ₹145.37, compared to a current price of ₹66.42 — trading 54.3% below its estimated fair value. The current Current Ratio is 2.14, which is 81% below median its 10-year median of 11.02 and 52.9% above the Medical Distribution industry median of 1.40. Novelix Pharmaceuticals' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current Current Ratio is 2.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novelix Pharmaceuticals (BOM:536565) Overvalued in 2026?
Based on GuruFocus' analysis, Novelix Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹66.42 is trading 54.3% below its estimated GF Value™ of ₹145.37.
GuruFocus considers Novelix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for BOM:536565:
Current Ratio: 2.14 (81% below median its 10-year median of 11.02)
GF Value™: ₹145.37 vs. price of ₹66.42 (54.3% below fair value)
Industry Position: 52.9% above the Medical Distribution median (#24 of 119)
No single metric tells the full story. See the BOM:536565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
62GF Score
Get the complete analysis for BOM:536565
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:536565 has been successfully added to your 
